Pharmacometrics and systems pharmacology for metabolic bone diseases

par Riggs, Matthew M., Cremers, Serge
Publié dans Br J Clin Pharmacol (2019)

Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling With mrgsolve: A Hands‐On Tutorial

par Elmokadem, Ahmed, Riggs, Matthew M., Baron, Kyle T.
Publié dans CPT Pharmacometrics Syst Pharmacol (2019)

A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations

par Eudy, Rena J., Riggs, Matthew M., Gastonguay, Marc R.
Publié dans AAPS J (2015)

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

par Johnston, Curtis K., Eudy-Byrne, Rena J., Elmokadem, Ahmed, Nock, Valerie, Marquard, Jan, Soleymanlou, Nima, Riggs, Matthew M., Liesenfeld, Karl-Heinz
Publié dans Pharmaceutics (2021)

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

par Riggs, Matthew M, Seman, Leo J, Staab, Alexander, MacGregor, Thomas R, Gillespie, William, Gastonguay, Marc R, Woerle, Hans J, Macha, Sreeraj
Publié dans Br J Clin Pharmacol (2014)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

par Perkins, Bruce A., Soleymanlou, Nima, Rosenstock, Julio, Skyler, Jay S., Laffel, Lori M., Liesenfeld, Karl‐Heinz, Neubacher, Dietmar, Riggs, Matthew M., Johnston, Curtis K., Eudy‐Byrne, Rena J., Elmokadem, Ahmed, George, Jyothis T., Marquard, Jan, Nock, Valerie
Publié dans Diabetes Obes Metab (2020)